

Not for release or distribution in the United States

1 May 2019

NZX/ASX Code: EBO

EBOS announces successful completion of NZ\$175 million share placement

EBOS Group Limited ("EBOS") is pleased to announce the successful completion of the underwritten institutional placement (the "Placement") of 8,883,249 new fully paid ordinary shares to raise NZ\$175 million. The issue price of NZ\$19.70 represented an 8.0% discount to the closing price on NZX of \$21.42 on 29 April 2019. The Placement was strongly supported by a broad range of existing and new investors across New Zealand, Australia and offshore.

John Cullity, EBOS Chief Executive Officer, said: "We are delighted with the strong support for the Placement and in particular, the level of demand from our shareholders and other investors. The proceeds provide EBOS with enhanced financial capacity for further strategic acquisitions and organic growth initiatives to continue the long term growth of the Group."

EBOS Chairman, Mark Waller added, "Our strategy has clearly resonated with investors. It is very pleasing to see the support EBOS has received with this placement. We look forward to continuing to successfully grow both our Healthcare and Animal care segments to create further shareholder value."

To accommodate the strong demand from investors the size of the Placement was increased to NZ\$175 million from the initial offer size of approximately NZ\$150 million announced on 30 April 2019. Following the allocation of the Placement shares, EBOS' pro-forma Net Debt / EBITDA as at 31 December 2018 will decrease to 1.51x (from 2.16x).¹

EBOS' ordinary shares will recommence trading upon market open today. Settlement of the Placement is expected to occur on Friday 3 May and Monday 6 May for the ASX and NZX respectively, with allotment of all shares on Monday 6 May. The new shares issued under the Placement will rank equally with existing EBOS ordinary shares. No shareholder approval is required to undertake the Placement.

UBS New Zealand Limited acted as Sole Lead Manager and Underwriter for the Placement.

¹ Pro-forma Net Debt : EBITDA ratio is calculated as the net debt at period end to the last 12 months EBITDA, adjusting for pre-acquisition earnings of acquisitions for the period and excluding one-off items

For further information, please contact:

Media:

New Zealand

Geoff Senescall, Senescall Akers

+64 21 481 234

Australia

James Aanensen, PRX

+61 410 518 590

Investor Relations:

Mark Connell

Investor Relations Manager, EBOS Group Ltd

+61 402 995 519

About EBOS Group

EBOS Group Limited is the largest and most diversified Australasian marketer, wholesaler and distributor of healthcare, medical and pharmaceutical products. It is also a leading marketer and distributor of recognised consumer products and animal care brands.

Not for distribution or release in the United States

This announcement may not be released to US wire services or distributed in the United States.

This announcement does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States or any other jurisdiction in which such an offer would be illegal. The new shares of EBOS have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act") or the securities laws of any state or other jurisdiction of the United States. Accordingly, the new shares may not be offered or sold, directly or indirectly, to persons in the United States except in a transaction exempt from, or not subject to, the registration requirements of the U.S. Securities Act and applicable securities laws of any state or other jurisdiction of the United States.